Avantor
AVTR
$9.39
-2.79%
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, operating through its Laboratory Solutions and Bioscience Production segments. The company is a significant player in the life sciences supply chain, offering a comprehensive portfolio of high-purity materials, consumables, equipment, and services that are essential for research, development, and production. The current investor narrative is dominated by concerns over margin pressure and supply chain risks, as highlighted by recent news regarding potential cost increases for critical medical supplies due to geopolitical disruptions in the Strait of Hormuz, which could directly impact Avantor's input costs and profitability.…
AVTR
Avantor
$9.39
Investment Opinion: Should I buy AVTR Today?
Rating & Thesis: Hold. Avantor presents a high-risk, high-potential-reward turnaround situation where deep valuation (PS of 1.19x) is counterbalanced by severe fundamental headwinds (negative margins, -9.53% ROE). The lack of a consensus analyst price target underscores the uncertainty, but the forward PE of 11.04x suggests the market is pricing in a recovery.
Supporting Evidence: The primary valuation metric, the PS ratio of 1.19x, is low and suggests the stock is not expensive on a sales basis. The company is expected to return to profitability, with analyst EPS estimates averaging $1.04. Technically, the stock has shown a strong short-term rebound of +19.31% over one month. However, this is contrasted by a negative trailing EPS of -$0.07 and an operating margin of -3.76%, which highlight the operational challenges that must be overcome for the valuation to be justified.
Risks & Conditions: The two biggest risks are 1) the failure to achieve forecasted profitability, invalidating the forward PE thesis, and 2) further gross margin compression from rising input costs, as highlighted in recent news. This Hold rating would upgrade to a Buy if the company reports consecutive quarters of positive operating income and demonstrates gross margin stability above 32%. It would downgrade to a Sell if the stock breaks below its 52-week low of $7.27 on deteriorating fundamentals. Relative to its own distressed state, the stock appears fairly valued, discounting both the turnaround potential and the significant execution risk.
Sign up to view all
AVTR 12-Month Price Forecast
The outlook for AVTR is bifurcated between its depressed valuation and its operational challenges. The base case is a volatile, range-bound stock as the company grinds through a difficult turnaround. The recent rally suggests a sentiment shift, but it lacks the fundamental confirmation of sustained margin improvement or profit generation. The stance is neutral because the risk of further fundamental deterioration (bear case) is balanced by the potential for a valuation snap-back if execution improves (bull case). Confidence is medium due to limited analyst coverage and the high sensitivity of the thesis to input costs. The stance would upgrade to bullish on evidence of quarter-over-quarter operating margin expansion; it would downgrade to bearish on a breakdown below the $7.27 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Avantor's 12-month outlook, with a consensus price target around $12.21 and implied upside of +30.0% versus the current price.
Average Target
$12.21
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$8 - $12
Analyst target range
Analyst coverage is limited, with only 4 analysts providing estimates, indicating this is a smaller-cap stock with less institutional scrutiny, which can contribute to higher volatility and less efficient price discovery. The available data provides consensus estimates for EPS and revenue but does not include a consensus price target, target price range, or buy/hold/sell ratings; therefore, the implied upside/downside, analyst sentiment, and the assumptions behind high and low targets cannot be calculated or discussed.
Bulls vs Bears: AVTR Investment Factors
The investment debate for Avantor is a classic tension between deep value and broken fundamentals. The bull case rests on a compelling valuation (PS of 1.19x), a recent technical rebound, and the expectation of a profitability turnaround (forward PE of 11x). The bear case is grounded in the harsh reality of current unprofitability, severe margin pressure exacerbated by supply chain risks, and catastrophic long-term stock performance. Currently, the bearish evidence appears stronger, as the company's negative margins and ROE represent fundamental operational failures that must be corrected before valuation can matter. The single most important tension is whether management can execute a turnaround to achieve the profitability implied by the forward PE multiple, or if rising input costs and operational challenges will perpetuate the value trap. The recent rally suggests hope, but it lacks fundamental confirmation.
Bullish
- Deeply Undervalued on Sales Basis: The stock trades at a trailing Price-to-Sales (PS) ratio of 1.19x, a historically low multiple for a mission-critical life sciences supplier. This valuation, near a 52-week low of $7.27, suggests significant pessimism is already priced in, offering a potential margin of safety.
- Strong Recent Momentum Reversal: The stock has rallied 19.31% over the past month and 18.41% over three months, diverging sharply from its one-year decline of -30.65%. This technical rebound from deeply oversold levels indicates a potential shift in sentiment and buying interest.
- Healthy Liquidity and Moderate Leverage: The company maintains a solid current ratio of 1.78, indicating adequate short-term liquidity to navigate challenges. Its debt-to-equity ratio of 0.71 is moderate, suggesting the balance sheet is not overextended.
- Market Expects Return to Profitability: Despite a negative trailing PE, the forward PE ratio stands at 11.04x, implying analysts expect a significant earnings recovery. The average EPS estimate of $1.04 for the next period points to a clear path out of unprofitability.
Bearish
- Severe Profitability and Margin Pressure: The company is currently unprofitable with a trailing EPS of -$0.07, a net margin of -8.09%, and an operating margin of -3.76%. Recent news highlights specific risks of rising petrochemical costs from geopolitical disruptions, which could further compress its 32.65% gross margin.
- Catastrophic Long-Term Price Performance: The stock has significantly underperformed the market, down 30.65% over one year with a maximum drawdown of -52.5%. Its Relative Strength vs. the S&P 500 is -53.51% over the same period, indicating severe and persistent selling pressure.
- Inefficient Use of Shareholder Capital: The company generates a negative Return on Equity (ROE) of -9.53%, meaning it destroys shareholder value. While ROA is positive at 2.78%, it remains low, suggesting assets are not being deployed effectively to generate profits.
- High Short Interest and Limited Analyst Coverage: A short ratio of 3.86 indicates significant bearish bets against the stock. Furthermore, with only 4 analysts providing estimates, there is less institutional scrutiny and support, which can lead to higher volatility and inefficient price discovery.
AVTR Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -30.65% and trading at a price of $9.39, which is approximately 59% of its 52-week range ($7.27 to $15.93), positioning it closer to its lows and suggesting a potential value opportunity amidst significant fundamental headwinds. Recent momentum shows a sharp but volatile recovery, with a 1-month price change of +19.31% and a 3-month change of +18.41%, indicating a potential short-term reversal or relief rally that diverges from the longer-term downtrend; however, this rally has been volatile, as evidenced by the stock's significant drawdown of -52.5% over the period. Key technical support is clearly defined at the 52-week low of $7.27, while resistance lies near the 52-week high of $15.93; a sustained break below support would signal a continuation of the bearish trend, while a move above recent highs near $10 would suggest a more durable recovery, and with a beta of 0.96, the stock's volatility is roughly in line with the broader market.
Beta
0.96
0.96x market volatility
Max Drawdown
-52.5%
Largest decline past year
52-Week Range
$7-$16
Price range past year
Annual Return
-30.6%
Cumulative gain past year
| Period | AVTR Return | S&P 500 |
|---|---|---|
| 1m | +19.3% | +0.3% |
| 3m | +18.4% | +10.9% |
| 6m | -15.9% | +9.3% |
| 1y | -30.6% | +24.3% |
| ytd | -18.1% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AVTR Fundamental Analysis
Revenue trajectory data is not available from the provided inputs, preventing an analysis of growth trends, segment performance, or quarterly comparisons. Profitability metrics show the company is currently unprofitable, with a trailing EPS of -$0.07 and a net margin of -8.09%, though it maintains a gross margin of 32.65%; the negative operating margin of -3.76% indicates operational challenges, and the path to profitability remains a key uncertainty for investors. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.71 and a healthy current ratio of 1.78, suggesting adequate short-term liquidity; however, with a negative Return on Equity (ROE) of -9.53% and a positive Return on Assets (ROA) of 2.78%, the company is not efficiently generating returns for shareholders from its equity base, though it is generating some return on its total assets.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AVTR Overvalued?
Given the negative trailing Net Income (implied by negative EPS), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 1.19x; a forward PE ratio of 11.04x is also provided, but its relevance is limited without positive earnings, though the gap between negative trailing and positive forward PE suggests the market anticipates a return to profitability. Peer comparison data for industry average valuation multiples is not available, preventing a determination of whether the PS ratio of 1.19x represents a premium or discount to the sector. Historical context for the stock's own valuation range (e.g., historical PS ratios) is also not available, so it cannot be assessed if the current multiple is near its own historical highs or lows.
PE
-14.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Avantor faces acute profitability risks, with a negative net margin of -8.09% and operating margin of -3.76%. The path to positive earnings is uncertain and critical to the investment thesis. Furthermore, the company's negative ROE of -9.53% indicates it is destroying shareholder capital, raising questions about capital allocation efficiency. While the balance sheet shows moderate leverage (D/E of 0.71), any prolonged period of cash burn or margin compression could pressure liquidity despite a healthy current ratio of 1.78.
Market & Competitive Risks: The stock's valuation presents a paradox. While the PS ratio of 1.19x appears cheap, the extreme EV/EBITDA of 81.8x reflects market skepticism about near-term cash generation. The stock has demonstrated high idiosyncratic risk, with a 52.5% max drawdown and severe underperformance vs. the S&P 500 (relative strength of -53.5% over one year). Externally, the recent news regarding petrochemical cost increases from Strait of Hormuz disruptions is a direct, quantifiable threat to gross margins, which currently stand at 32.65%. As a company with a beta of 0.96, its volatility is market-aligned, but its fundamental challenges make it vulnerable to sector-wide de-ratings.
Worst-Case Scenario: The worst-case scenario involves a failure to achieve forecasted profitability, compounded by sustained input cost inflation from geopolitical supply chain disruptions. This could lead to continued margin erosion, cash flow deterioration, and a breach of the recent 52-week low of $7.27. In this adverse scenario, the stock could re-test its lows, implying a downside of approximately -22% from the current price of $9.39. A prolonged period of unprofitability could also trigger credit rating concerns or a more aggressive short-selling campaign, given the already elevated short ratio of 3.86.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company is currently unprofitable (EPS -$0.07) and may fail to achieve its forecasted turnaround. 2) Margin Risk: Recent news highlights specific threats of rising petrochemical costs, which could compress its 32.65% gross margin further. 3) Market Sentiment Risk: The stock has a high short ratio (3.86) and has dramatically underperformed the market (-30.65% over one year), indicating persistent negative sentiment. 4) Execution Risk: With a negative ROE of -9.53%, there is a risk that management cannot deploy capital effectively to generate shareholder returns.
The 12-month forecast for AVTR is highly uncertain, with three distinct scenarios. The base case (50% probability) sees the stock trading between $9.50 and $11.50 as it makes slow progress on its turnaround. The bull case (25% probability) could see a rally to $12.50-$15.00 on successful execution and margin improvement. The bear case (25% probability) risks a decline to the $7.27-$8.50 range if profitability disappoints and costs rise. The most likely outcome is the base case, which assumes the company meets its EPS estimates but struggles to re-rate meaningfully higher.
AVTR sends mixed valuation signals, making it difficult to classify cleanly. On a sales basis, it appears undervalued with a trailing PS ratio of 1.19x. However, based on earnings and cash flow, it looks expensive or broken, with a negative trailing PE and an extremely high EV/EBITDA of 81.8x. The forward PE of 11.04x suggests the market is valuing it based on expected future profits. Overall, the stock is likely fairly valued relative to its current distressed state, discounting both the potential for recovery and the significant risk of failure.
AVTR is a high-risk, potentially high-reward stock that may be a good buy only for speculative investors with a high risk tolerance and a long-term horizon. The current Price-to-Sales ratio of 1.19x suggests it is not overvalued, and the forward PE of 11.04x prices in a significant earnings recovery. However, with negative current profitability (-8.09% net margin) and clear risks from rising input costs, it is not a good buy for conservative investors. The decision hinges entirely on one's belief in management's ability to execute a turnaround.
AVTR is unsuitable for short-term trading due to its high volatility, limited analyst coverage, and sensitivity to earnings news and cost headlines. It is best approached as a long-term, speculative investment with a minimum horizon of 2-3 years. This timeframe is necessary to allow management's turnaround plan to unfold, for the expected profitability (EPS $1.04) to materialize, and for the market to re-assess the story. The stock's beta of 0.96 means it moves with the market, but its idiosyncratic turnaround risks dominate its near-term price action.